AP
Insider
ARCH Venture Fund XIII, L.P.
10% ownerARCH Venture Fund XIII, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Lyell Immunopharma, Inc. (LYEL). Across 1 priced purchase filing, the average 21-session return was +0.4% from execution and -6.9% from disclosure (delay-adjusted; derived). The largest single filing was $12.5M of LYEL (488,090 sh × $25.61, as filed), executed Mar 6.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+0.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-6.9%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$12.5M
shares × price, as filed
Last traded
Mar 6
Filed Mar 9
Median ADV $2.9M across their filed names
Open performance→Volume by month
Buys $12.5M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
LYELRecent filings
LYELPURCHASE
Lyell Immunopharma, Inc.
View filing →
$12.5M488,090 sh × $25.61
Exec Mar 6
Filed Mar 9 · 4:34 PM ET